Cost-effectiveness of intraperitoneal chemohyperthermia in the treatment of peritoneal carcinomatosis from colorectal cancer

Value in Health

Volumn 11, Issue 3, 2008, Pages 347-353

  Bonastre, Julia ^a   Chevalier, Julie ^a   Elias, Dominique ^a   Classe, Jean Marc ^b   Ferron, Gwenaël ^c   Guilloit, Jean Marc ^d   Marchal, Frédéric ^e   Meeus, Pierre ^f   De Pouvourville, Gerard ^g  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE RENÉ GAUDUCHEAU   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d Cancer Institute   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

^f CENTRE LÉON BÉRARD   (France)

^g ESSEC BUSINESS SCHOOL   (France)

Author keywords

Cost censored data; Cost effectiveness; Intraperitoneal chemohyperthermia; Peritoneal carcinomatosis from colorectal cancer; Restricted mean survival

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARCINOMATOUS PERITONITIS; CENSORSHIP; COLORECTAL CANCER; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; FRANCE; HOSPITALIZATION COST; HUMAN; HYPERTHERMIC THERAPY; INTRAPERITONEAL CHEMOHYPERTHERMIA; KAPLAN MEIER METHOD; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS;

EID: 44049107812     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2007.00249.x     Document Type: Article

References (28)

1. GD Jayne S Fook C Loi Peritoneal carcinomatosis from colorectal cancer Br J Surg 89 2002 1545 1550
2. PH Sugarbaker WJ Cunliffe JF Belliveau Rationale for perioperative intraperitoneal chemotherapy as a surgical adjuvant for gastrointestinal malignancy Reg Cancer Treat 1 1988 66 79
3. G Begossi S Gonzalez-Moreno G Ortega-Perez Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma Eur J Surg Oncol 28 2002 80 87
4. AT Culliford AD Brooks S Sharma Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer Ann Surg Oncol 8 2001 787 795
5. E de Bree AJ Witkamp FA Zoetmulder Intraperitoneal chemotherapy for colorectal cancer J Surg Oncol 79 2002 46 61
6. P Shen EA Levine J Hall Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis Arch Surg 138 2003 26 33
7. D Elias F Blot A El Otmany Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy Cancer 92 2001 71 76
8. BW Loggie RA Fleming RP McQuellon Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin Am Surg 66 2000 561 568
9. P Piso H Bektas U Werner Improved prognosis following peritonectomy procedures and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from appendiceal carcinoma Eur J Surg Oncol 27 2001 286 290
10. VJ Verwaal S Van Ruth E de Bree Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer J Clin Oncol 21 2003 3737 3743
11. VJ Verwaal S Van Ruth A Witkamp Long-term survival of peritoneal carcinomatosis of colorectal origin Ann Surg Oncol 12 2005 65 71
12. J Bryant AJ Clegg MK Sidhu Clinical effectiveness and costs of the Sugarbaker procedure for the treatment of pseudomyxoma peritonei Health Technol Assess 8 2004 1 54
13. PH Sugarbaker BM Ronnett A Archer Pseudomyxoma peritonei syndrome Adv Surg 30 1996 233 280
14. J Bonastre P Jan G de Pouvourville Cost of an intraperitoneal chemohyperthermia (IPCH) related to cytoreductive surgery Ann Chir 130 2005 553 561
15. D Elias JR Delperro L Sideris Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials Ann Surg Oncol 11 2004 518 521
16. O Glehen F Kwiatkowski PH Sugarbaker Cytoreductive surgery combined with perioperative chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study J Clin Oncol 22 2004 3284 3292
17. DY Lin EJ Feuer R Etzioni Y Wax Estimating medical costs from incomplete follow-up data Biometrics 53 1997 419 434
18. H Bang AA Tsiatis Estimating medical costs with censored data Biometrika 87 2000 329 343
19. JO Irwin The standard error of an estimate of expectational life J Hyg (Lond) 47 1949 457 481
20. TG Karrison Use of Irwin's restricted mean as an index for comparing survival in different treatment groups––interpretation and power considerations Control Clin Trials 18 1997 151 167
21. R Peto MC Pike P Armitage Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples Br J Cancer 35 1977 1 39
22. H Jiang XH Zhou Bootstrap confidence intervals for medical costs with censored observations Stat Med 23 2004 3365 3376
23. C Hill Should comparison be made between survival of responding vs. non-responding patients? Bull Cancer 80 1993 294 298
24. RH Chapman M Berger MC Weinstein When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ 13 2004 429 436
25. TO Tengs Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter? Value Health 7 2004 70 78
26. L Longworth T Young MJ Buxton Midterm cost-effectiveness of the liver transplantation program of England and Wales for three disease groups Liver Transpl 9 2003 1295 1307
27. J Wilson M Connock F Song Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation Health Technol Assess 9 2005 1 142
28. EB Elkin MC Weinstein EP Winer HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis J Clin Oncol 22 2004 854 863